Phase II trial of an AKT inhibitor (perifosine) for recurrent glioblastoma.

Thomas J KaleyKatherine S PanageasIngo K MellinghoffCraig NolanIgor T GavrilovicLisa M DeAngelisLauren E AbreyEric C HollandAndrew B Lassman

Published in: Journal of neuro-oncology (2019)

PRF is tolerable but ineffective as monotherapy for GBM. Preclinical data suggests synergistic effects of PRF in combination with other approaches, and further study is ongoing.

Keyphrases

open label
cell proliferation
electronic health record
randomized controlled trial
stem cells
big data
machine learning
deep learning
mesenchymal stem cells
study protocol